Clearmind's MEAI reduces body weight, improves fatty liver disease and normalizes insulin sensitivity in rodents
Jan. 9, 2023
Clearmind Medicine Inc. has released promising preclinical results demonstrating efficacy of its psychedelic-derived drug candidate MEAI for treating obesity and metabolic syndrome.
